Dapagliflozin is used for treating heart failure and type 2 diabetes. It was first introduced by Astrazeneca Ab in its drug Farxiga on Jan 8, 2014. 2 different companies have introduced drugs containing Dapagliflozin.

Dapagliflozin Patents

Given below is the list of patents protecting Dapagliflozin, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Farxiga	US12213988	Methods of treating chronic kidney disease with dapagliflozin	Apr 01, 2041	Astrazeneca Ab
Farxiga	US10973836 (Pediatric)	Methods of treating heart failure with reduced ejection fraction	Sep 09, 2040	Astrazeneca Ab
Farxiga	US11903955 (Pediatric)	Methods of treating heart failure with reduced ejection fraction	Sep 09, 2040	Astrazeneca Ab
Farxiga	US10973836	Methods of treating heart failure with reduced ejection fraction	Mar 09, 2040	Astrazeneca Ab
Farxiga	US11903955	Methods of treating heart failure with reduced ejection fraction	Mar 09, 2040	Astrazeneca Ab
Farxiga	US11826376 (Pediatric)	Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same	Jan 18, 2040	Astrazeneca Ab
Farxiga	US11826376	Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same	Jul 18, 2039	Astrazeneca Ab
Farxiga	US8685934 (Pediatric)	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	Nov 26, 2030	Astrazeneca Ab
Farxiga	US8721615 (Pediatric)	Ampoule comprising an ampoule holder	Jul 18, 2030	Astrazeneca Ab
Farxiga	US7919598 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	Jun 16, 2030	Astrazeneca Ab
Farxiga	US8685934	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	May 26, 2030	Astrazeneca Ab
Farxiga	US8721615	Ampoule comprising an ampoule holder	Jan 18, 2030	Astrazeneca Ab
Farxiga	US7919598	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec 16, 2029	Astrazeneca Ab
Farxiga	US7851502 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	Feb 19, 2029	Astrazeneca Ab
Farxiga	US8221786 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	Sep 21, 2028	Astrazeneca Ab
Farxiga	US8361972 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	Sep 21, 2028	Astrazeneca Ab
Farxiga	US8716251 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	Sep 21, 2028	Astrazeneca Ab
Farxiga	US7851502	Pharmaceutical formulations containing an SGLT2 inhibitor	Aug 19, 2028	Astrazeneca Ab
Farxiga	US8221786	Pharmaceutical formulations containing an SGLT2 inhibitor	Mar 21, 2028	Astrazeneca Ab
Farxiga	US8361972	Pharmaceutical formulations containing an SGLT2 inhibitor	Mar 21, 2028	Astrazeneca Ab
Farxiga	US8716251	Pharmaceutical formulations containing an SGLT2 inhibitor	Mar 21, 2028	Astrazeneca Ab
Farxiga	US8501698 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec 20, 2027	Astrazeneca Ab
Farxiga	US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	Jun 20, 2027	Astrazeneca Ab
Farxiga	US8329648 (Pediatric)	Methods for treating diabetes and reducing body weight	Feb 18, 2027	Astrazeneca Ab
Farxiga	US8906851 (Pediatric)	Method for treating diabetes	Feb 18, 2027	Astrazeneca Ab
Farxiga	US8329648	Methods for treating diabetes and reducing body weight	Aug 18, 2026	Astrazeneca Ab
Farxiga	US8906851	Method for treating diabetes	Aug 18, 2026	Astrazeneca Ab
Farxiga	US6515117 (Pediatric)	C-aryl glucoside SGLT2 inhibitors and method	Apr 04, 2026	Astrazeneca Ab
Farxiga	US7456254 (Pediatric)	Polymer-based sustained release device	Dec 30, 2025	Astrazeneca Ab
Farxiga	US8431685 (Pediatric)	Polymer-based sustained release device	Oct 13, 2025	Astrazeneca Ab
Farxiga	US8461105 (Pediatric)	Polymer-based sustained release device	Oct 13, 2025	Astrazeneca Ab
Farxiga	US6515117	C-aryl glucoside SGLT2 inhibitors and method	Oct 04, 2025	Astrazeneca Ab
Farxiga	US7456254	Polymer-based sustained release device	Jun 30, 2025 (Expired)	Astrazeneca Ab
Farxiga	US8431685	Polymer-based sustained release device	Apr 13, 2025 (Expired)	Astrazeneca Ab
Farxiga	US8461105	Polymer-based sustained release device	Apr 13, 2025 (Expired)	Astrazeneca Ab
Farxiga	US9238076	Polymer-based sustained release device	Apr 15, 2024 (Expired)	Astrazeneca Ab
Farxiga	US6414126	C-aryl glucoside SGLT2 inhibitors and method	Oct 04, 2020 (Expired)	Astrazeneca Ab
Farxiga	US6936590	C-aryl glucoside SGLT2 inhibitors and method	Oct 04, 2020 (Expired)	Astrazeneca Ab
Farxiga	US9198925	Pharmaceutical formulations containing an SGLT2 inhibitor	Oct 04, 2020 (Expired)	Astrazeneca Ab

Add above patents to watchlist

Dapagliflozin's Family Patents

Full family tree

Dapagliflozin Generic API Manufacturers

Several generic applications have been filed for Dapagliflozin.

Given below is the list of companies who have filed for Dapagliflozin generic, along with the locations of their manufacturing plants worldwide.